Pacira Pharmaceuticals (PCRX) Is Today's Dead Cat Bounce Stock
- PCRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $38.7 million.
- PCRX has traded 99,472 shares today.
- PCRX is up 3.1% today.
- PCRX was down 6.7% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in PCRX with the Ticky from Trade-Ideas. See the FREE profile for PCRX NOW at Trade-Ideas More details on PCRX: Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. Currently there are 6 analysts that rate Pacira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Pacira Pharmaceuticals has been 481,200 shares per day over the past 30 days. Pacira has a market cap of $2.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.31 and a short float of 20.4% with 6.93 days to cover. Shares are up 12% year-to-date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Pacira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and disappointing return on equity. Highlights from the ratings report include:
- The debt-to-equity ratio is very high at 2.43 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Along with the unfavorable debt-to-equity ratio, PCRX maintains a poor quick ratio of 0.72, which illustrates the inability to avoid short-term cash problems.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, PACIRA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- PACIRA PHARMACEUTICALS INC has improved earnings per share by 28.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, PACIRA PHARMACEUTICALS INC reported poor results of -$1.93 versus -$1.73 in the prior year. This year, the market expects an improvement in earnings (-$0.32 versus -$1.93).
- The gross profit margin for PACIRA PHARMACEUTICALS INC is rather high; currently it is at 50.32%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -35.62% is in-line with the industry average.
- Net operating cash flow has significantly increased by 70.34% to -$6.28 million when compared to the same quarter last year. In addition, PACIRA PHARMACEUTICALS INC has also vastly surpassed the industry average cash flow growth rate of 11.22%.
- You can view the full Pacira Pharmaceuticals Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.